drug
tofersen sodium
Marketedupdated 3mo agoby $BIIB BIOGEN INC.
Approvedcommunity read0 votes
indications
investigational
ALS
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 25, 2028
~1.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Apr 1, 2035compositionUS 10385341
- Apr 1, 2035method-of-use (U-3575)US 10669546
- Apr 1, 2035method-of-use (U-3575)US 10968453
FDA exclusivities (2)
- Apr 25, 2030ODE-432Orphan Drug (7y)3.7y
- Apr 25, 2028NCENew Chemical Entity (5y)1.7y
News(1)
- Biogen’s targeted ALS treatment is reversing decline in some patients. Can more be helped?Three years after Qalsody was approved by the FDA as the first drug to target a genetic cause of ALS, some patients are reporting not only disease stabilization but also improvement of symptoms.biospace · 8d ago
Data sources
last refreshed 29m ago
Found something off?
comments(0)
5-min edit window · permanent after that